Document Detail


Histone deacetylases as targets for treatment of multiple diseases.
MedLine Citation:
PMID:  23414309     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
HDACs (histone deacetylases) are a group of enzymes that deacetylate histones as well as non-histone proteins. They are known as modulators of gene transcription and are associated with proliferation and differentiation of a variety of cell types and the pathogenesis of some diseases. Recently, HDACs have come to be considered crucial targets in various diseases, including cancer, interstitial fibrosis, autoimmune and inflammatory diseases, and metabolic disorders. Pharmacological inhibitors of HDACs have been used or tested to treat those diseases. In the present review, we will examine the application of HDAC inhibitors in a variety of diseases with the focus on their effects of anti-cancer, fibrosis, anti-inflammatory, immunomodulatory activity and regulating metabolic disorders.
Authors:
Jinhua Tang; Haidong Yan; Shougang Zhuang
Related Documents :
22366379 - Association of repeated exposure to antibiotics with the development of pediatric crohn...
8457929 - Lysosomal storage diseases in livestock.
23182329 - Cutaneous manifestations of internal diseases.
9506659 - A new mutation of the glucose-6-phosphatase gene in a 4-year-old girl with oligosymptom...
6255119 - Neutropenia and impaired neutrophil migration in type ib glycogen storage disease.
18039129 - Autophagy: basic principles and relevance to disease.
22232719 - Porphyromonas endodontalis in chronic periodontitis: a clinical and microbiological cro...
22194359 - Bioenergetic origins of complexity and disease.
22206179 - An interview with dr kenneth kornman. interview by david w richards.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical science (London, England : 1979)     Volume:  124     ISSN:  1470-8736     ISO Abbreviation:  Clin. Sci.     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-02-18     Completed Date:  2013-04-26     Revised Date:  2013-05-21    
Medline Journal Info:
Nlm Unique ID:  7905731     Medline TA:  Clin Sci (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  651-62     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Tongji University School of Medicine, Shanghai East Hospital, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylation / drug effects
Antineoplastic Agents / therapeutic use*
Apoptosis / genetics
Autophagy / genetics
Cell Cycle Checkpoints / genetics
Epigenomics
Fibrosis / drug therapy*
Histone Deacetylase Inhibitors / therapeutic use*
Histone Deacetylases / metabolism,  physiology*
Histones / metabolism
Humans
Immunity / genetics
Immunomodulation / drug effects*
Metabolic Diseases / drug therapy*
Neoplasms / drug therapy*
Grant Support
ID/Acronym/Agency:
DK-071997/DK/NIDDK NIH HHS; DK-085065/DK/NIDDK NIH HHS; R01 DK085065/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Histone Deacetylase Inhibitors; 0/Histones; EC 3.5.1.98/Histone Deacetylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gene expression of TRAF-1 and TRAF-2 in inflammatory bowel disease.
Next Document:  Conference Scene: A symphony on C: orchestrating DNA repair for gene expression via cytosine modific...